You are here:

canakinumab (Ilaris)

Advice

in the absence of a submission from the holder of the marketing authorisation

canakinumab (Ilaris ®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • tumour necrosis factor  receptor associated periodic syndrome
  • hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
  • Familial Mediterranean Fever

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: canakinumab (Ilaris)
SMC Drug ID: 1268/17
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:
BNF Category:
Status: Not Recommended
Date Advice Published: 7 August 2017

Back